Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Collection
Publisher
Years
  • 1
    ISSN: 1569-8041
    Keywords: failure-free survival ; IL-10 ; Hodgkin's disease
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Interleukin-10 (IL-10) is a pleiotropic cytokine that protects B- or T-lymphocytes and hemopoietic progenitors from apoptosis induced by doxorubicin, glucocorticoids, or deprivation of growth factors. IL-10 is also immunosupressive, and tumor cells secreting IL-10 can grow in syngeneic or allogeneic hosts, and can inhibit the generation of tumor-specific cytotoxic T cells. Hodgkin-Reed–Sternberg cells are derived from follicular center B cells and they may be latently infected by EBV. When this occurs they often express IL-10. Based on these considerations we investigated the relationship between pretreatment serum IL-10 levels and failure-free survival (FFS) in Hodgkin's disease (HD). Patients and methods: Untreated patients, older than 16 years, with biopsy-proven HD, were included if treated with ABVD or equivalent regimens, and if pretreatment serum was available. IL-10 levels were determined with a capture enzyme-linked immunoassay specific for cellular IL-10. Results: Among healthy adult volunteers serum IL-10 levels ranged from 4.8–9.8 pg/ml (mean 7.1, standard deviation 1.5 pg/ml). Therefore levels ≥10 pg/ml were considered elevated. We identified 101 patients with available serum. Their median age was 32 years, and 60% had B-symptoms. Ann Arbor stage was I in 4, II in 21, III in 35, and IV in 41 patients. Histology was nodular sclerosis in 74, mixed cellularity in 12, lymphocyte predominance in six, lymphocyte depletion in one, and unclassified in eight patients. Pretreatment serum IL-10 levels were elevated in 51 patients, and were higher in those with serum albumin 〈3.5 g/dl, B symptoms, serum β2-microglobulin ≥2.5 mg/l, anemia, and AAS III or IV. After a median follow-up of 32 months for survivors, 20 patients have progressed, and the three-year FFS of those with high vs. normal serum IL-10 was 60% ± 9 vs. 91 ± 9% (50% vs. 50% of the population; P = 0.004 by log-rank). Among patients with Ann Arbor stage III or IV the three-year FFS for those with high vs. normal serum IL-10 (58 vs. 42% of the population) was 57 ± 9% vs. 92 ± 6% (P = 0.008 by log-rank). Multivariate analysis using Cox's proportional hazards model confirmed that IL-10 was an independent variable associated with inferior FFS in this population. Conclusions: Elevation of serum IL-10 levels is frequent and is associated with inferior FFS in adults with ABVD-treated HD. This observation should be verified in other patient populations. In addition, the source and the role of IL-10 in the biology of HD should be further investigated.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Mit Grundlagen und Innovationen auf dem Gebiet der Krebstherapie und Krebsdiagnostik beschäftigte sich der Workshop in Jena. Den 18 Teilnehmern von allen Kontinenten vermittelten die Jenaer Experten Grundkenntnisse zu aktuellen Aspekten der Krebsforschung. Sechs Abteilungen der Friedrich-Schiller-Universität, des Hans-Knöll-Institutes für Naturstoff-Forschung e.V. (HKI) und des Institutes für Molekulare Biotechnologie (IMB) machten die Gäste aus 13 Ländern (u.a. Honduras, Mongolei, Sudan und Ungarn) in praktischen Übungen und Seminaren mit neuen Ansätzen der Tumormedizin vertraut. Den Kursteilnehmern sollte etwas von der Aufbruchstimmung vermittelt werden, die durch neue Erkenntnisse der Molekularbiologie und Zellbiologie in der Krebsforschung gegenwärtig festzustellen ist. In diesem Sinne demonstrierte der Workshop auch die enge Kooperation der Grundlagenforscher und Mediziner in Jena.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Der Onkologe 5 (1999), S. 891-897 
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Innerhalb der letzten Jahre ist deutlich geworden, daß Veränderungen der Apoptose im Sinne eines „Zuviel” oder „Zuwenig” die pathophysiologische Grundlage zahlreicher Krankheiten wie Tumorerkrankungen, Virusinfektionen, Autoimmunerkrankungen, neurodegenerativer Störungen, AIDS sowie hämatologischer Systemerkrankungen wie aplastischer Anämie und myelodysplastischer Syndrome (MDS) darstellen. Eine Modulation der apoptotischen Schwelle in therapeutischer Intention als Resultat des besseren Verständnisses dieser Prozesse besitzt ein enormes Potential zur Beeinflussung des Verlaufs vieler Krankheiten und repräsentiert vielversprechende neue Behandlungsansätze. Die vorliegende Übersicht bietet einen komprimierten Überblick der derzeitigen Konzepte.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 62 (1991), S. 83-83 
    ISSN: 1432-0584
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1569-8041
    Keywords: CD30L ; CD40L ; FasL ; Hodgkin's disease
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Reed–Sternberg cells of Hodgkin's disease express CD30and CD40 receptors. The ligands for these receptors have been reported to have pleiotropic biologic activities in vitro, including induction of cell death. Expression of the ligands for these receptors in lymph nodes involved with Hodgkin's disease is not known. Purpose: The purpose of this study was to examine CD30 ligand (L) andCD40L expression in lymph nodes of patients with Hodgkin's disease, and to study CD30L expression on nodal lymphocyte subsets. Materials and methods: CD30L expression on subsets of lymphocytes of five lymph nodes involved with Hodgkin's disease was determined by two-color FACScan. Messenger RNA expression of CD30L and CD40L was determined by there verse-transcriptase polymerase chain reaction (RT-PCR) method performed on seven specimens involved with Hodgkin's disease (five lymph nodes and two spleens). Results: Four of seven specimens (57%) contained cells that expressed CD30L mRNA and three specimens (43%) containedCD40L-expressing cells. The mean percentage of nodal lymphocytes expressingCD30L surface protein was ≤20%. Conclusion: Hodgkin's disease lymph nodes and spleens frequently lackCD30L- and CD40L-expressing cells, and when CD30L is expressed, it is usually detected on few numbers of lymphocytes. The differences in the level of expression of these ligands in Hodgkin's disease lymph nodes may be related to the disease's clinical behavior.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1569-8041
    Keywords: CD30L ; CD40L ; FasL ; Hodgkin's disease
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Reed–Sternberg cells of Hodgkin's disease express CD30and CD40 receptors. The ligands for these receptors have been reported tohave pleiotropic biologic activities in vitro, including induction of celldeath. Expression of the ligands for these receptors in lymph nodes involvedwith Hodgkin's disease is not known. Purpose: The purpose of this study was to examine CD30 ligand (L) andCD40L expression in lymph nodes of patients with Hodgkin's disease, and tostudy CD30L expression on nodal lymphocyte subsets. Materials and methods: CD30L expression on subsets of lymphocytes of fivelymph nodes involved with Hodgkin's disease was determined by two-colorFACScan. Messenger RNA expression of CD30L and CD40L was determined by thereverse-transcriptase polymerase chain reaction (RT-PCR) method performed onseven specimens involved with Hodgkin's disease (five lymph nodes and twospleens). Results: Four of seven specimens (57%) contained cells thatexpressed CD30L mRNA and three specimens (43%) containedCD40L-expressing cells. The mean percentage of nodal lymphocytes expressingCD30L surface protein was ≤20%. Conclusion: Hodgkin's disease lymph nodes and spleens frequently lackCD30L- and CD40L-expressing cells, and when CD30L is expressed, it is usuallydetected on few numbers of lymphocytes. The differences in the level ofexpression of these ligands in Hodgkin's disease lymph nodes may be relatedto the disease's clinical behavior.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...